brilacidin (PMX-30063) / Innovation Pharma - LARVOL DELTA

Screening of the Pandemic Response Box library identified promising compound candidate drug combinations against extensively drug-resistant Acinetobacter baumannii. (PubMed, Sci Rep) - "The combination of MUT056399 and brilacidin against A. baumannii QS17-1084 and that of MUT056399 and eravacycline against A. baumannii 5075 showed bactericidal activity. Our findings highlight the drug combinations as promising candidates for further evaluation in murine wound infection models against multidrug-resistant A. baumannii. These compounds hold potential for addressing the critical need for effective antibiotics in the face of rising antimicrobial resistance."

Journal • Preclinical • Infectious Disease • Malaria

New Highly Selective Antivirals for Chikungunya Virus identified from the Screening of a Drug-Like Compound Library. (PubMed, Curr Microbiol) - "Our screening approach successfully identified previously reported CHIKV antiviral compounds within this library and further expanded potentially active hits, supporting the use of reporter-virus-based assays in high-throughput screening format as a reliable tool for antiviral drug discovery. Four molecules were identified as potential drug candidates against CHIKV: MMV1634402 (Brilacidin) and MMV102270 (Diphyllin), which were previously shown to present broad-spectrum antiviral activities, in addition to MMV1578574 (Eravacycline), and the antifungal MMV689401 (Fluopicolide), for which their antiviral potential is uncovered here."

Journal • Preclinical • Chikungunya • Immunology • Infectious Disease • Rheumatology

Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungus Aspergillus fumigatus. (PubMed, Microbiol Spectr) - "BRI + IBX can inhibit the growth of A. fumigatus voriconazole- and caspofungin-resistant clinical isolates. BRI is a small molecule host defense peptide mimetic that has previously exhibited broad-spectrum immunomodulatory/anti-inflammatory activity against bacteria and viruses. We propose the combination of BRI and IBX as a new antifungal combinatorial treatment against aspergillosis."

Journal • Infectious Disease • Malaria • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Busting Cryptococcus with brilacidin. (PubMed, Nat Rev Microbiol) - No abstract available

Journal

Brilacidin, a novel antifungal agent against Cryptococcus neoformans. (PubMed, mBio) - "We investigated the mechanism of action of BRI and BRI + CAS against C. neoformans. We propose BRI as a new antifungal agent against cryptococcosis."

Journal • CNS Disorders • Infectious Disease • Malaria • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Antifungal Activity of Brilacidin, a Nonpeptide Host Defense Molecule. (PubMed, Antibiotics (Basel)) - "We studied brilacidin, an arylamide of this type, for its activity in vitro against fungi (40 clinical isolates, 20 species) that the World Health Organization has highlighted as problem human pathogens. We found antifungal activity at low concentrations for many pathogens, which indicates that further screening for activity, particularly in vivo, is justified to evaluate this compound, and other mimetics, as attractive leads for the development of effective antifungal agents."

Journal

Brilacidin as a Broad-Spectrum Inhibitor of Enveloped, Acutely Infectious Viruses. (PubMed, Microorganisms) - "The inhibitory potential of brilacidin against the viruses tested in this study was dependent on the dosing strategy which necessitated compound addition pre- and post-infection, with addition only at the post-infection stage not eliciting a robust inhibitory response. The inhibitory activity of brilacidin was only modest in the context of the non-enveloped Picornavirus Echovirus, suggesting brilacidin may be less potent against non-enveloped viruses."

Journal • CNS Disorders • Hematological Disorders • Hepatology • Infectious Disease • Liver Failure • Musculoskeletal Pain • Ophthalmology • Respiratory Diseases

Identification of Novel, Potent, and Selective Compounds against Malaria Using Glideosomal-Associated Protein 50 as a Drug Target. (PubMed, ACS Omega) - "Using different screening methods, eight compounds (Hayatinine, Curine, MMV689758 (Bedaquiline), MMV1634402 (Brilacidin), and MMV688271, MMV782353, MMV642550, and USINB4-124-8) were identified, which showed promising binding affinity (KD 100 fold for malaria parasite. These eight compounds were effective against Chloroquine-resistant PfINDO and Artemisinin-resistant PfCam3.1 strains...Importantly, the oral delivery of Bedaquiline (50 mg/kg b. wt.) showed substantial suppression of parasitemia, and three out of seven mice were cured of the infection. Thus, our study provides new scaffolds for the development of antimalarials that can act at multiple Plasmodium lifecycle stages."

Journal • Infectious Disease • Malaria

Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases (GlobeNewswire) - "Innovation Pharmaceuticals...announced the United States Patent and Trade Office (USPTO), on June 6, 2023, granted a patent, 'Host Defense Protein (HDP) Mimetics for Prophylaxis and/or Treatment of Inflammatory Diseases of the Gastrointestinal Tract,' and also recently issued a Notice of Allowance for the patent application, 'Arylamide Compounds For Treatment Of Viral Infections'....Related to the claims of these newly allowed patents, Brilacidin has been tested in Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS) (by rectal enema administration), where most patients achieved clinical remission, with further progress made in the development of an oral Brilacidin formulation for treatment of Ulcerative Colitis and Crohn’s Disease."

Patent • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi. (PubMed, Nat Commun) - "BRI alone also decreases A. fumigatus fungal burden and ablates disease development in a murine model of fungal keratitis. Our results indicate that combinations of BRI and antifungal drugs in clinical use are likely to improve the treatment outcome of aspergillosis and other fungal infections."

Journal • Infectious Disease • Keratitis • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases

"$IPIX Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers https://t.co/VcKbdzVHPc" (@otcdynamics)

"$IPIX Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium https://t.co/RFCaDZn70t" (@otcdynamics)

Brilacidin, a Non-Peptide Defensin-Mimetic Molecule, Inhibits SARS-CoV-2 Infection by Blocking Viral Entry. (PubMed, EC Microbiol) - "The inhibitory effect on viral entry was not mediated through blocking the binding of either the spike receptor-binding domain or the spike S1 protein to hACE2 proteins. Taken together, brilacidin inhibits SARS-CoV-2 infection by blocking viral entry and is active against SARS-CoV-2 variants."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

"Woops! Brilacidin (sp)" (@loofymectin)

Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases (BioSpace) - "Brilacidin oral formulation development work for Ulcerative Colitis continues. The Company has also been notified by Alfasigma, its licensing partner, of their intent to initiate this year Phase 2 testing of Brilacidin in Ulcerative Proctitis/Proctosigmoiditis."

New P2 trial • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell. (PubMed, J Med Virol) - "Drug combination therapy showed that brilacidin has a strong synergistic effect with remdesivir against HCoV-OC43 in cell culture. Drug combination therapy showed that brilacidin has a strong synergistic effect with remdesivir against HCoV-OC43 in cell culture. Taken together, this study provides appealing findings for the translational potential of brilacidin as a broad-spectrum antiviral for coronaviruses including SARS-CoV-2."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

"Speaking of mucosal immunity: active vitamin D & human defensin? The DoD surely must have completed studies on Brilacidin by now. Where is it?" (@loofymectin)

"Dr. Boulware, where's the Brilacidin??" (@loofymectin)

"Dr B. did you see this? Brilacidin / per DoD https://t.co/CfDp6yT9ME" (@loofymectin)

A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19 (clinicaltrials.gov) - P2; N=120; Completed; Sponsor: Innovation Pharmaceuticals, Inc.; Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • PCR

"Is Brilacidin going to be next EUA" (@Washik_Khan)

Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium (GlobeNewswire) - "Innovation Pharmaceuticals...announced that antiviral research related to Brilacidin has been accepted for an Oral Presentation at the 2021 Military Health System Research Symposium (MHSRS), taking place August 23-26, 2021, at the Gaylord Palms Resort and Convention Center, Kissimmee, FL. The MHSRS is an annual four-day scientific symposium sponsored by the U.S. Department of Defense....New data supporting Brilacidin’s broad spectrum antiviral properties will be presented at the 2021 MHSRS conference, as well as during a separate oral presentation on Brilacidin to be delivered at the American Society of Virology’s 40th Annual Meeting, to be held in July."

Preclinical • Infectious Disease • Novel Coronavirus Disease

Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19 (GlobeNewswire) - "Innovation Pharmaceuticals...has achieved full patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients...Complete trial enrollment comprised 120 dosed patients recruited across multiple sites. Final data collection for the last patient enrolled in the study is expected to occur in early August (Study Day 60), which will then be followed by the process of unblinding study data and the reporting of topline study results."

Enrollment closed • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19 (clinicaltrials.gov) - P2; N=120; Active, not recruiting; Sponsor: Innovation Pharmaceuticals, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • PCR

Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19 (GlobeNewswire) - "Innovation Pharmaceuticals...announces that patient enrollment in the Company’s 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 has reached 90 percent and that the Company anticipates full enrollment to be completed in approximately two weeks....The Phase 2 study is a randomized, double-blind, placebo-controlled clinical trial evaluating Brilacidin, a synthetic, non-peptidic small molecule drug candidate in a new class of compounds called defensin-mimetics, at domestic and international sites. The Company intends to provide an update to shareholders upon the final patients entering the trial."

Enrollment status • Infectious Disease • Novel Coronavirus Disease